covid test
  • Defence Therapeutics (DTC) has announced the development of a second-generation COVID vaccine, AccuVAC-IN002
  • The new vaccine induces both IgA and IgG antibody responses at mucosal sites ensuring a transmission-blocking effect
  • The AccuVAC-IN002 formulation can be further developed to become a “universal” vaccine capable of targeting 4-8 strains simultaneously
  • Defence Therapeutics is a biotechnology company working on engineering the next-generation vaccines and ADC products using its proprietary platform
  • Defence Therapeutics Inc. (DTC) opened trading at C$7.60 per share

Defence Therapeutics (DTC) has announced the development of a second-generation COVID vaccine, AccuVAC-IN002, for intranasal delivery.

Initially, vaccination against SARS2-COVID was efficient at slowing down viral spreading across the globe. However, the arrival of new and more infectious strains is challenging the efficacy of current vaccines for two main reasons. First, detected mutations can escape generated humoral responses. Second, researchers found that people infected with the Delta strain carry 1260 times more viruses in their nasal cavity compared to the original version of the coronavirus. The latter point is extremely important as current vaccination strategies do not ensure protection from this airborne transmission at mucosal sites, which represent the initial site of infection. This means that vaccinated individuals can still be infected and possibly develop life-threatening symptoms.

“With Defence’s new AccuVAC-IN002 formulation, we are able to induce both IgA and IgG antibody responses both systemically and at mucosal sites. This would ensure a transmission-blocking effect that will not only halt initial infection but will also ensure close to a 100 per cent blockade in viral shedding” says Mr. Plouffe, the CEO of Defence Therapeutics.

“In addition, our new AccuVAC-IN002 formulation can be further developed to become a “universal” vaccine capable of targeting 4-8 strains simultaneously, which would provide effective protection against all known variants and future emerging strains,” he added.

The AccuVAC-IN002 is one of the vaccines designed and developed by Defence to advance against the SARS-COVID virus. The current progression of the SARS-COVID virus suggests that we may be facing a new influenza-like seasonal virus requiring a new vaccine every 6-12 months. Defence is therefore dedicated to fighting this airborne disease and any other emerging pathogens through its vaccine development program.

In addition to its vaccine development for infectious disease, Defence is advancing on its DC vaccine program against cancer with its AccuVAC-D001. Development and additional news on the DC vaccine for cancer will be released in the near future. Defence and its AccumTM technology platform position the company on the path for the future development of universal therapeutic vaccines for cancer and infectious diseases.

Defence Therapeutics is a biotechnology company working on engineering the next-generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illnesses such as cancer and infectious diseases.

Defence Therapeutics Inc. (DTC) opened trading at C$7.60 per share.

More From The Market Online

Usha Resources begins phase 4 fieldwork at White Willow Project

Usha Resources (TSXV:USHA) has begun the fourth phase of fieldwork at its White Willow Lithium Project in Ontario following phase 3 work.

@ the Bell: Stocks level-out ahead of Easter long weekend

A rebound in oil prices and growth in metal prices helped push Canada’s main stock index higher as investors await economic data.